June 16, 2023
National Cancer Institute (NCI)
The purpose of this Notice is to correct the Key Dates in RFA-CA-23-015, Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional).
Currently reads:
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
June 13, 2023 | June 13, 2023 | Not Applicable | October 2024 | January 2024 | April 2024 |
November 17, 2023 | November 17, 2023 | Not Applicable | March 2024 | May 2024 | July 2024 |
Corrected to read (in bold italics):
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
June 13, 2023 | June 13, 2023 | Not Applicable | October 2023 | January 2024 | April 2024 |
November 17, 2023 | November 17, 2023 | Not Applicable | March 2024 | May 2024 | July 2024 |
All other aspects of RFA-CA-23-015 remain unchanged.
Scientific/Research Contact(s)
Juli Klemm, Ph.D.
National Cancer Institute (NCI)
Telephone: 202-853-7889
Email: [email protected]
Peer Review Contact(s)
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]
Financial/Grants Management Contact(s)
Sean Hine
National Cancer Institute (NCI)
Telephone: 240-276-6291
E-mail: [email protected]